Zevra Therapeutics' average 12-month price target has been raised to $25.25 by eight analysts, with a unanimous 'Buy' rating from nine covering analysts. This implies a significant potential upside of 146% from the stock's closing price on October 30, 2026, suggesting strong analyst confidence in the company's future performance.
The filing indicates that Zevra Therapeutics has received an increased 12-month price target of $25.25 from eight analysts, with a unanimous 'Buy' rating from nine analysts. This is a positive development for ZVRA as it signals strong confidence from the analyst community, implying a substantial potential upside of 146%. For traders, this could lead to short-term upward price momentum as investors react to the favorable analyst sentiment. Long-term implications depend on the company's ability to meet these expectations, but the current consensus suggests a bullish outlook. The key opportunity for traders is to capitalize on potential price appreciation driven by this positive news.